Author:
Whitlock James A.,Horton Terzah M.
Reference62 articles.
1. Schultz KR, Pullen DJ, Sather HN, et al. Risk- and response-based classification of childhood B-precursor acute lymphoblastic leukemia: a combined analysis of prognostic markers from the Pediatric Oncology Group (POG) and Children’s Cancer Group (CCG). Blood. 2007;109:926–935.
2. Gaynon PS, Camitta BC, Matloub Y, et al. Outcomes for B-precursor patients in Legacy Children’s Cancer Group (CCG) and Pediatric Oncology Group (POG) studies in childhood acute lymphoblastic leukemia (ALL): A Children’s Oncology Group (COG) report. ASH Annual Meeting Abstracts. 2007;110:847.
3. Gaynon PS, Harris RE, Altman AJ, et al. Bone marrow transplantation versus prolonged intensive chemotherapy for children with acute lymphoblastic leukemia and an initial bone marrow relapse within 12 months of the completion of primary therapy: Children’s Oncology Group study CCG-1941. J Clin Oncol. 2006;24:3150–3156.
4. Raetz EA, Borowitz MJ, Devidas M, et al. Reinduction Platform for Children With First Marrow Relapse of Acute Lymphoblastic Leukemia: A Children’s Oncology Group Study. J Clin Oncol. 2008;26:3971–3978.
5. Gaynon PS. Childhood acute lymphoblastic Leukemia and relapse. Br J Haematol. 2005;131:579–587.